Early medical abortion

References

• Swahn ML, Bygdeman M. Medical methods to terminate pregnancy. In: Baillière’s Clinical Obstetrics and Gynaecology (Volume 4). Medical Induction of Abortion. Bygdeman M (Ed.). Bailliére Tindall, London, UK, 292–306 (1990).
   Google Scholar
• Kovacs L, Sas M, Resch BA et al. Termination of pregnancy by RU 486 – an antiprogestational compound. Contraception29, 399–410 (1984).
   PubMed Web of Science ®Google Scholar
• Shoupe D, Mishell MR Jr, Brenner PF, Spitz IM. Pregnancy termination with a high and medium dosage of RU 486. Contraception33, 455–461 (1986).
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn ML. Progesterone receptor blockage – effect on uterine contractility and early pregnancy. Contraception32, 45–51 (1985).
   PubMed Web of Science ®Google Scholar
• Wiebe E, Dunn S, Guilbert E, Jacot F, Lustig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet. Gynecol.99, 813–819 (2002).
   PubMed Web of Science ®Google Scholar
• Ferris LE, Basinski AS. Medical abortion: what does the research tell us? Can. Med. Assoc. J.154, 185–187 (1996).
   Google Scholar
• Henshaw RC, Naji SA, Russell I, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women’s preferences and acceptability of treatment. Br. Med. J.307, 714–717 (1993).
   PubMed Web of Science ®Google Scholar
• Winikoff B. Acceptability of medical abortion in early pregnancy. Fam. Plann. Perspect.27, 142–148 (1995).
   PubMedGoogle Scholar
• Van Look PFA, Bydgeman M. Antiprogestational steroids: a new dimension in human fertility control. Reprod. Bio. Rev. (Oxf.)11, 1–60 (1989).
   Google Scholar
• Birgerson L, Olund A, Odlind V, Somell C. Termination of early human pregnancy with epostane. Contraception35, 111–120 (1987).
   PubMed Web of Science ®Google Scholar
• Le Roux PA, van der Spuy ZM. Labor induction abortion utilizing trilostane, a 3b-hydroxysteroid dehydrogenase inhibitor. Contraception71, 343–347 (2005).
   Google Scholar
• Komanicky P, Spark RF, Melby JC. Treatment of Cushing’s syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metabol.47, 1042–1051 (1978).
   PubMed Web of Science ®Google Scholar
• Swahn ML, Kovacs L, Cekan SZ, Aedo AR, Westlund P. Termination of early pregnancy with ZK 98,734: pharmacokinetic behavior and clinical effect. Hum. Reprod.9, 57–63 (1994).
   Google Scholar
• Heikinheimo O, Kekkonen R. Dose-response relationship of RU 486. Ann. Med.25, 71–76 (1993).
   PubMed Web of Science ®Google Scholar
• Baird DT. Mode of action of medical methods of abortion. J. Am. Med. Womens Assoc.55, 121–126 (2000).
   Google Scholar
• World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. Br. Med. J.30, 532–537 (1993).
   Google Scholar
• World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. Br. J. Obstet. Gynaecol.107, 524–530 (2000).
   Google Scholar
• World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Medical abortion at 57 to 63 days gestation with a lower dose of mifepristone and gemeprost. A randomized controlled trial. Acta Obstet. Gynecol. Scand.80, 447–451 (2001).
   PubMedGoogle Scholar
• Kulier R, Gülmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev.1, CD002855 (2006).
   Google Scholar
• World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Lowering the doses of mifepristone and gemeprost for early abortion: a randomized controlled trial. Br. J. Obstet. Gynaecol.108, 738–742 (2001).
   Google Scholar
• Collins PW. Misoprostol: discovery, development and clinical applications. Med. Res. Rev.10, 149–172 (1990).
   Google Scholar
• Kotsonis FN, Dodd DC, Regnier B, Kohn FE. Preclinical toxicology profile of misoprostol. Dig. Dis. Sci.11(Suppl. 11), 142S–146S (1985).
   Google Scholar
• Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med.338, 1241–1247 (1998).
   PubMed Web of Science ®Google Scholar
• El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N. Engl. J. Med.332, 983–987 (1995).
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Honkanen H, Piaggio G et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. Br. J. Obstet. Gynaecol.110, 808–818 (2003).
   Google Scholar
• Honkanen H, Piaggio G, von Hertzen H et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II: side effects and women's perceptions. Br. J. Obstet. Gynaecol.111, 715–725 (2004).
   Google Scholar
• Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum. Reprod.17, 332–336 (2002).
   PubMed Web of Science ®Google Scholar
• Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum. Reprod.15, 1159–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum. Reprod.19, 81–84 (2004).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br. J. Obstet. Gynaecol.109, 1281–1289 (2002).
   Google Scholar
• WHO. Safe Abortion: Technical and Policy Guidance for Health Systems. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Royal College of Obstetricians and Gynaecologists. National Evidence-based Clinical Guidelines: The Care of Women Requesting Induced Abortion. Updated Guidelines. RCOG, London, UK (2004).
   Google Scholar
• Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br. J. Obstet. Gynaecol.95, 126–134 (1988).
   PubMedGoogle Scholar
• Ashok PW, Flett GM, Templeton A. Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. Am. J. Obstet. Gynecol.183, 998–1002 (2000).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding SL, Westhoff C et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA284, 1948–1953 (2000).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception64, 81–85 (2001).
   PubMed Web of Science ®Google Scholar
• Davey A. Mifepristone and prostaglandin for termination of pregnancy: contraindications for use. Reasons and rationale. Contraception74, 16–20 (2006).
   Google Scholar
• Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception47, 85–95 (1993).
   Web of Science ®Google Scholar
• Vogel D, Burkhardt T, Rentsch K et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am. J. Obstet. Gynecol.191, 2168–2173 (2004).
   PubMed Web of Science ®Google Scholar
• Xu J, Chen H, Ma T, Wu X. Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol. Int. J. Gynaecol. Obstet.72, 245–251 (2001).
   PubMedGoogle Scholar
• Ashok PW, Penney GC, Flett GMM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum. Reprod.13, 2962–2965 (1998).
   PubMed Web of Science ®Google Scholar
• Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception70, 183–190 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer M, Bhatnagar J, Guarner J et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N. Engl. J. Med.353, 2352–2360 (2005).
   PubMed Web of Science ®Google Scholar
• Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann. Pharmacother.40, 191–197 (2006).
   PubMedGoogle Scholar
• Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet352, 323 (1998).
   PubMed Web of Science ®Google Scholar
• Elger W, Neef G, Ottow E et al. Studies on interactions of antiprogestins with prostaglandins and sex hormone-related agents at the myometrial level in pregnant guinea pigs. In: Hormone Antagonists for Fertility Regulation. Puri CP, Van Look PFA (Eds). Good Print Publishers, Bombay, India, 105–121 (1995).
   Google Scholar